Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53

Cell Cycle

Volumn 11, Issue 24, 2012, Pages 4570-4578

  Da Costa, Nathalia Meireles ^a,b,f   Hautefeuille, Agnès ^b   Cros, Marie Pierre ^b   Melendez, Matias Eliseo ^c   Waters, Timothy ^d   Swann, Peter ^d   Hainaut, Pierre ^b,e   Pinto, Luis Felipe Ribeiro ^a,f  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c CNRS   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^f INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Base excision repair; Epigenetic stability; Glycosylase; Mutator phenotype; p53; TDG; Transcriptional regulation

Indexed keywords

LUCIFERASE; MESSENGER RNA; PROTEIN P53; THYMINE DNA GLYCOSYLASE;

ARTICLE; BREAST CANCER; BRONCHUS MUCOSA; CANCER CELL CULTURE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; DNA RESPONSIVE ELEMENT; EPITHELIUM CELL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENETIC STABILITY; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TEMPERATURE SENSITIVITY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WILD TYPE;

EID: 84871498059     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22843     Document Type: Article

References (66)

1. Krawczak M, Ball EV, Cooper DN. Neighboring-nucleotide effects on the rates of germ-line single-basepair substitution in human genes. Am J Hum Genet 1998; 63:474-88; PMID:9683596; http://dx.doi.org/10.1086/301965.
2. Tomso DJ, Bell DA. Sequence context at human single nucleotide polymorphisms: overrepresentation of CpG dinucleotide at polymorphic sites and suppression of variation in CpG islands. J Mol Biol 2003; 327:303-8; PMID:12628237; http://dx.doi.org/10.1016/S0022-2836(03)00120-7.
3. Waters TR, Swann PF. Thymine-DNA glycosylase and G to A transition mutations at CpG sites. Mutat Res 2000; 462:137-47; PMID:10767625; http://dx.doi.org/10.1016/S1383-5742(00)00031-4.
4. Kumar S, Subramanian S. Mutation rates in mammalian genomes. Proc Natl Acad Sci USA 2002; 99:803-8; PMID:11792858; http://dx.doi.org/10.1073/pnas. 022629899.
5. Wiebauer K, Jiricny J. In vitro correction of G.T mispairs to G.C pairs in nuclear extracts from human cells. Nature 1989; 339:234-6; PMID:2716851; http://dx.doi.org/10.1038/339234a0.
6. Cortázar D, Kunz C, Saito Y, Steinacher R, Schär P. The enigmatic thymine DNA glycosylase. DNA Repair (Amst) 2007; 6:489-504; PMID:17116428; http://dx.doi.org/10.1016/j.dnarep.2006.10.013.
7. Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 1999; 401:301-4; PMID:10499592; http://dx.doi.org/10.1038/45843.
8. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998; 18:6538-47; PMID:9774669.
9. Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Genuardi M, Karbowski M, et al. Investigation of the substrate spectrum of the human mismatchspecific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain. J Cell Physiol 2000; 185:473-80; PMID:11056019; http://dx.doi. org/10.1002/1097- 4652(200012)185:3〈473::AIDJCP19〉3.0.CO;2-#.
10. Millar CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, Hendrich B, et al. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 2002; 297:403-5; PMID:12130785; http://dx.doi.org/10.1126/science.1073354.
11. INK4a) and hMLH1 genes. Mol Cell Biol 2005; 25:4388-96; PMID:15899845; http://dx.doi.org/10.1128/MCB.25.11.4388-4396.2005.
12. Cortázar D, Kunz C, Selfridge J, Lettieri T, Saito Y, MacDougall E, et al. Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability. Nature 2011; 470:419-23; PMID:21278727; http://dx.doi.org/10.1038/nature09672.
13. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011; 146:67-79; PMID:21722948; http://dx.doi.org/10.1016/j.cell.2011.06.020.
14. Chen D, Lucey MJ, Phoenix F, Lopez-Garcia J, Hart SM, Losson R, et al. T:G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha. J Biol Chem 2003; 278:38586-92; PMID:12874288; http://dx.doi.org/10.1074/ jbc.M304286200.
15. Li YQ, Zhou PZ, Zheng XD, Walsh CP, Xu GL, Li YQ. Association of Dnmt3a and thymine DNA glycosylase links DNA methylation with base-excision repair. Nucleic Acids Res 2007; 35:390-400; PMID:17175537; http://dx.doi.org/10.1093/ nar/gkl1052.
16. Gallais R, Demay F, Barath P, Finot L, Jurkowska R, Le Guével R, et al. Deoxyribonucleic acid methyl transferases 3a and 3b associate with the nuclear orphan receptor COUP-TFI during gene activation. Mol Endocrinol 2007; 21:2085-98; PMID:17579209; http://dx.doi.org/10.1210/me.2006-0490.
17. Tini M, Benecke A, Um SJ, Torchia J, Evans RM, Chambon P. Association of CBP/p300 acetylase and thymine DNA glycosylase links DNA repair and transcription. Mol Cell 2002; 9:265-77; PMID:11864601; http://dx.doi.org/10. 1016/S1097-2765(02)00453-7.
18. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009; 14:597-606; PMID:19259822; http://dx.doi.org/10.1007/s10495-009-0330-1.
19. Adimoolam S, Ford JM. p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst) 2003; 2:947-54; PMID:12967652; http://dx.doi.org/10.1016/S1568-7864(03)00087-9.
20. Hussain SP, Harris CC. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. J Nippon Med Sch 2006; 73:54-64; PMID:16641528; http://dx.doi.org/10.1272/jnms.73.54.
21. Bocangel D, Sengupta S, Mitra S, Bhakat KK. p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res 2009; 29:3741-50; PMID:19846904.
22. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993; 119:441-9; PMID:8509434; http://dx.doi.org/10.1007/BF01215923.
23. Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R, Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 1997; 71:79-87; PMID:9096669; http://dx.doi.org/10.1002/ (SICI)1097-0215(19970328)71:1〈79::AID-IJC14〉3.0.CO;2-4.
24. Guimarães DP, Oliveira IM, de Moraes E, Paiva GR, Souza DM, Barnas C, et al. Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer 2009; 124:272-9; PMID:19003964; http://dx.doi.org/10.1002/ijc.23944.
25. Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, et al. BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 2000; 27:57-64; PMID:10657898; http://dx.doi.org/ 10.1002/(SICI)1098-2744(200002)27:2〈57::AIDMC1〉3.0.CO;2-I.
26. Guimarães DP, Hainaut P. TP53: a key gene in human cancer. Biochimie 2002; 84:83-93; PMID:11900880; http://dx.doi.org/10.1016/S0300- 9084(01)01356-6.
27. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 275:36316-23; PMID:10961991; http://dx.doi.org/10.1074/jbc.M004293200.
28. Hardeland U, Steinacher R, Jiricny J, Schär P. Modification of the human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzymatic turnover. EMBO J 2002; 21:1456-64; PMID:11889051; http://dx.doi.org/10.1093/ emboj/21.6.1456.
29. Steinacher R, Schär P. Functionality of human thymine DNA glycosylase requires SUMO-regulated changes in protein conformation. Curr Biol 2005; 15:616-23; PMID:15823533; http://dx.doi.org/10.1016/j.cub.2005.02.054.
30. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 2002; 33:181-8; PMID:11870884; http://dx.doi.org/ 10.1002/mc.10038.
31. Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, et al. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996; 12:2535-47; PMID:8700512.
32. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21:2933-42; PMID:15860560; http://dx.doi.org/10.1093/bioinformatics/bti473.
33. Menendez D, Inga A, Snipe J, Krysiak O, Schönfelder G, Resnick MA. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol 2007; 27:2590-600; PMID:17242190; http://dx.doi.org/10.1128/MCB.01742-06.
34. Waters TR, Swann PF. Kinetics of the action of thymine DNA glycosylase. J Biol Chem 1998; 273:20007-14; PMID:9685338; http://dx.doi.org/10.1074/jbc.273. 32.20007.
35. Abu M, Waters TR. The main role of human thymine-DNA glycosylase is removal of thymine produced by deamination of 5-methylcytosine and not removal of ethenocytosine. J Biol Chem 2003; 278:8739-44; PMID:12493755; http://dx.doi.org/10.1074/jbc.M211084200.
36. Hardeland U, Bentele M, Jiricny J, Schär P. The versatile thymine DNA-glycosylase: a comparative characterization of the human, Drosophila and fission yeast orthologs. Nucleic Acids Res 2003; 31:2261-71; PMID:12711670; http://dx.doi.org/10.1093/nar/gkg344.
37. Neddermann P, Jiricny J. The purification of a mismatch-specific thymine-DNA glycosylase from HeLa cells. J Biol Chem 1993; 268:21218-24; PMID:8407958.
38. Um S, Harbers M, Benecke A, Pierrat B, Losson R, Chambon P. Retinoic acid receptors interact physically and functionally with the T:G mismatch-specific thymine-DNA glycosylase. J Biol Chem 1998; 273:20728-36; PMID:9694815; http://dx.doi.org/10.1074/jbc.273.33.20728.
39. Neddermann P, Gallinari P, Lettieri T, Schmid D, Truong O, Hsuan JJ, et al. Cloning and expression of human G/T mismatch-specific thymine-DNA glycosylase. J Biol Chem 1996; 271:12767-74; PMID:8662714; http://dx.doi.org/10. 1074/jbc.271.22.12767.
40. Su HL, Li SS. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 2002; 296:65-73; PMID:12383504; http://dx.doi.org/10.1016/S0378-1119(02)00843-0.
41. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004; 38:445-76; PMID:15568983; http://dx.doi.org/10.1146/annurev.genet.38.072902.092448.
42. Mohan RD, Rao A, Gagliardi J, Tini M. SUMO- 1-dependent allosteric regulation of thymine DNA glycosylase alters subnuclear localization and CBP/ p300 recruitment. Mol Cell Biol 2007; 27:229-43; PMID:17060459; http://dx.doi.org/10.1128/MCB.00323-06.
43. Read AP, Strachan T. Cancer Genetics. In: Read AP, Strachan T, eds. Human molecular genetics. 2nd ed. New York: Wiley- Liss Publ, 1999: 427-44.
44. Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010; 80:724-30; PMID:20450892; http://dx.doi.org/10.1016/j. bcp.2010.04.031.
45. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 1999; 450:197-204; PMID:10359074; http://dx.doi.org/10. 1016/S0014-5793(99)00505-0.
46. Zhou J, Ahn J, Wilson SHE, Prives C. A role for p53 in base excision repair. EMBO J 2001; 20:914-23; PMID:11179235; http://dx.doi.org/10.1093/emboj/ 20.4.914.
47. Seo YR, Fishel ML, Amundson S, Kelley MR, Smith ML. Implication of p53 in base excision DNA repair: in vivo evidence. Oncogene 2002; 21:731-7; PMID:11850801; http://dx.doi.org/10.1038/sj.onc.1205129.
48. Achanta G, Huang P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res 2004; 64:6233-9; PMID:15342409; http://dx.doi.org/10.1158/0008-5472.CAN-04-0494.
49. de Souza-Pinto NC, Harris CC, Bohr VA. p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria. Oncogene 2004; 23:6559-68; PMID:15208669; http://dx.doi.org/10.1038/sj.onc.1207874.
50. Wilson SH, Kunkel TA. Passing the baton in base excision repair. Nat Struct Biol 2000; 7:176-8; PMID:10700268; http://dx.doi.org/10.1038/82818.
51. Chatterjee A, Mambo E, Osada M, Upadhyay S, Sidransky D. The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOgg1) activity. FASEB J 2006; 20:112-4; PMID:16293709.
52. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/ science.1905840.
53. Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, et al. Integrity of p53 in hepatitis B x antigen-positive and -negative hepatocellular carcinomas. Cancer Res 1997; 57:426-32; PMID:9012469.
54. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675.
55. Loeb KR, Loeb LA. Genetic instability and the mutator phenotype. Studies in ulcerative colitis. Am J Pathol 1999; 154:1621-6; PMID:10362784; http://dx.doi.org/10.1016/S0002-9440(10)65415-6.
56. Loeb LA. Mutator phenotype in cancer: origin and consequences. Semin Cancer Biol 2010; 20:279-80; PMID:20937389; http://dx.doi.org/10.1016/j. semcancer.2010.10.006.
57. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003; 100:776-81; PMID:12552134; http://dx.doi.org/10.1073/pnas. 0334858100.
58. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11:220-8; PMID:20177397; http://dx.doi.org/10.1038/nrm2858.
59. Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75:1227-36; PMID:8261516; http://dx.doi. org/10.1016/0092-8674(93)90331-J.
60. Bhattacharyya NP, Skandalis A, Ganesh A, Groden J, Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA 1994; 91:6319-23; PMID:8022779; http://dx.doi.org/10.1073/pnas.91.14.6319.
61. Missero C, Pirro MT, Simeone S, Pischetola M, Di Lauro R. The DNA glycosylase T:G mismatch-specific thymine DNA glycosylase represses thyroid transcription factor-1-activated transcription. J Biol Chem 2001; 276:33569-75; PMID:11438542; http://dx.doi.org/10.1074/jbc.M104963200.
62. Zhu B, Benjamin D, Zheng Y, Angliker H, Thiry S, Siegmann M, et al. Overexpression of 5-methylcytosine DNA glycosylase in human embryonic kidney cells EcR293 demethylates the promoter of a hormone-regulated reporter gene. Proc Natl Acad Sci USA 2001; 98:5031-6; PMID:11296268; http://dx.doi.org/10. 1073/pnas.091097298.
63. Métivier R, Gallais R, Tiffoche C, Le Péron C, Jurkowska RZ, Carmouche RP, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008; 452:45-50; PMID:18322525; http://dx.doi.org/10.1038/ nature06544.
64. Kangaspeska S, Stride B, Métivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, et al. Transient cyclical methylation of promoter DNA. Nature 2008; 452:112-5; PMID:18322535; http://dx.doi.org/10.1038/nature06640.
65. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011; 333:1303-7; PMID:21817016; http://dx.doi.org/10.1126/science.1210944.
66. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 21:6722-8; PMID:12360399; http://dx.doi.org/10.1038/sj.onc.1205874.